查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046011

慢性鼻竇炎市場－全球產業規模、佔有率、趨勢、機會、預測：按疾病表現型、治療類型、分銷管道、地區和競爭格局分類，2021-2031年

Chronic Rhinosinusitis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Phenotype, By Treatment Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球慢性鼻竇炎 (CRS) 市場預計將從 2025 年的 31.2 億美元成長到 2031 年的 47.7 億美元，複合年成長率為 7.33%。

醫學上，慢性鼻竇炎（CRS）定義為鼻腔和鼻竇內膜持續性炎症，持續時間至少12週，通常表現為鼻塞、臉部壓迫感和嗅覺減退等症狀。推動市場成長的主要因素包括呼吸道過敏症盛行率上升和環境污染加劇，這兩者都會增加鼻竇發炎的易感性。此外，全球人口老化也顯著推高了市場需求，因為與老齡化相關的生理變化往往會加劇慢性鼻竇炎的症狀。根據美國耳鼻喉頭頸外科學會基金會的數據，到2025年，11.6%的成年人將患有慢性鼻竇炎，每年將導致410萬次門診就診。

市場概覽
預測期 2027-2031
市場規模：2025年 31.2億美元
市場規模：2031年 47.7億美元
複合年成長率：2026-2031年 7.33%
成長最快的細分市場 嗜酸性粒細胞慢性鼻竇炎
最大的市場 北美洲

然而，阻礙全球慢性鼻竇炎市場快速擴張的一大障礙是先進生物製藥療法和微創手術的高昂費用。儘管這些創新治療方法在對傳統療法無效的重症病例中展現出卓越的療效，但其高昂的費用常常給患者就醫和醫保報銷帶來挑戰，尤其是在對成本高度敏感的發展中地區。因此，這一經濟障礙可能會限制這些高價值治療方案的廣泛應用，從而抑制該行業的整體收入成長潛力。

市場促進因素

針對鼻息肉的生物目標療法的快速普及正在從根本上改變難治性慢性鼻竇炎的臨床治療方法。這些創新藥物特異性針對發炎通路，減少息肉負荷，並為恢復嗅覺提供了一種有效的非手術選擇。隨著臨床指南越來越支持將這些療法用於對皮質類固醇無反應的患者，市場正在迅速接受這些治療方法。例如，2024年10月，再生元製藥公司公佈了其2024年第三季商業性業績，顯示市場對該療法表現出濃厚的興趣。該公司報告稱，生物製藥的全球淨銷售額成長了23%，達到38.2億美元。這項銷售成長凸顯了在治療由2型發炎引起的鼻竇疾病方面，精準醫療正在成為更廣泛的趨勢。

同時，微創鼻竇手術的進步提供了更安全、更方便的門診治療方案，推動了市場擴張。諸如球囊鼻竇擴張術和類固醇釋放植入等技術顯著縮短了恢復時間，提高了患者的接受度。這種需求的成長得益於該疾病的高發生率。根據2024年11月發表在《臨床與實驗過敏》雜誌上的一篇報導，全球慢性鼻竇炎的總盛行率為8.71%，顯示有大量人口需要有效的治療。因此，醫療設備製造商正將此需求視為商機。根據史賽克公司於2025年1月發布的“2024年第四季及全年業績報告”，在穩定的手術需求支撐下，其醫療外科和神經技術部門（包括耳鼻喉科業務）的銷售額達到135億美元（同比成長11.1%）。

市場挑戰

先進生物療法和微創手術的高昂費用是全球慢性鼻竇炎市場擴張的主要障礙。儘管這些治療方法能為症狀難治的患者帶來顯著的臨床效益，但其高昂的價格限制了其廣泛應用。醫療系統，尤其是在資源匱乏地區的醫療系統，往往難以承擔這些高昂的費用，導致嚴格的報銷規定和處方藥清單限制。因此，這些治療方法的普及速度緩慢，迫使患者和醫療服務提供者選擇價格較低廉的傳統治療方法，但這些療法對於重症患者可能效果欠佳。

這些高成本治療方法的經濟影響巨大，導致支付方猶豫不決。歐洲鼻科學會期刊《鼻科學》（Rhinology）2025年的報告指出，生物製藥。如此高昂的費用阻礙了保險公司核准這些治療方法作為一線治療方案的批准。儘管臨床上對較佳治療效果的需求顯而易見，但這項經濟障礙直接降低了製藥公司的潛在利潤，並抑制了整體市場成長。

市場趨勢

新型緩釋鼻腔給藥系統的出現正在克服傳統噴霧劑和植入的不足。這些創新的呼氣給藥方式利用患者自身的呼吸將藥物輸送到鼻竇深處，促進藥物沉積，無需進行侵入性手術。這種方法正獲得越來越多尋求最大限度提高局部固醇療效的醫療專業人員的支持。專業創新公司取得的商業性成功也證明了這種給藥方式的日益普及。例如，Optinose公司於2025年1月發布新聞稿，公佈了其“2024年第四季度XHANCE未經審計的暫定淨銷售額”，報告稱該季度淨產品銷售額為2240萬美元。這顯示市場對該公司先進的給藥平台的需求持續旺盛。

同時，擴增實境（AR）技術在內視鏡鼻竇手術中的應用顯著提升了手術視野的清晰度和解剖結構的精確度。外科醫生擴大使用導航系統，將3D解剖數據直接投射到手術區域，從而最大限度地降低複雜手術中併發症的風險。這項進步與整個產業追求高精準度手術、減少組織損傷的目標相契合。因此，隨著醫院不斷升級手術設施，對先進醫療設備的需求仍然強勁。Medtronic在2024年5月發布的2024會計年度及第四季度財報中強調，其耳鼻喉科（ENT）業務（隸屬於其專科治療部門）實現了中等個位數的成長，這主要得益於動力設備和導航技術的強勁銷售。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球慢性鼻竇炎市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疾病表現型（嗜酸性粒細胞慢性鼻竇炎、嗜酸性粒細胞慢性鼻竇炎、感染性慢性鼻竇炎、過敏性黴菌性鼻竇炎、其他）
    • 治療方法（醫療設備、藥物、滴鼻劑、類固醇鼻噴霧、手術、其他）
    • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美慢性鼻竇炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲慢性鼻竇炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區慢性鼻竇炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲慢性鼻竇炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲慢性鼻竇炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球慢性鼻竇炎市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Lyra Therapeutics
  • Novartis AG
  • Medtronic plc
  • GlaxoSmithKline plc
  • AstraZeneca Plc
  • Sanofi AG
  • Dr. Reddy's Laboratories Ltd.
  • Stryker Corporation
  • Bayer AG
  • Smith & Nephew Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17457

The global market for Chronic Rhinosinusitis (CRS) is projected to expand from USD 3.12 billion in 2025 to USD 4.77 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 7.33%. CRS is medically defined as persistent inflammation of the nasal cavity and paranasal sinus lining for a minimum of twelve continuous weeks, typically presenting with symptoms such as nasal obstruction, facial pressure, and a diminished sense of smell. Key factors driving this market growth include the rising incidence of respiratory allergies and increased environmental pollution, both contributing to higher vulnerability to sinonasal inflammation. Furthermore, an aging global population significantly boosts demand, as age-related physiological changes often worsen chronic sinus conditions. Data from the American Academy of Otolaryngology-Head and Neck Surgery Foundation indicates that in 2025, 11.6% of adults were affected by CRS, leading to 4.1 million ambulatory visits annually.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.12 Billion
Market Size 2031USD 4.77 Billion
CAGR 2026-20317.33%
Fastest Growing SegmentEosinophilic Chronic Rhinosinusitis
Largest MarketNorth America

However, a notable obstacle hindering the swift expansion of the Global Chronic Rhinosinusitis Market is the considerable expense linked to advanced biologic therapies and minimally invasive surgical procedures. Despite these innovative treatments offering superior effectiveness for severe, unresponsive cases, their elevated costs frequently pose challenges for patient access and reimbursement, especially in cost-sensitive developing regions. This financial barrier may thus restrict the widespread uptake of these high-value therapeutic options, consequently moderating the sector's overall revenue growth potential.

Market Driver

The rapid uptake of targeted biologic therapies for nasal polyps is profoundly transforming the clinical approach to managing refractory chronic rhinosinusitis. These innovative agents specifically target inflammatory pathways, providing a powerful non-surgical option to reduce polyp load and restore the sense of smell. The market is quickly incorporating these treatments as clinical recommendations increasingly support their use for patients who do not respond to corticosteroids. For instance, Regeneron Pharmaceuticals reported in October 2024 that Dupixent, a prominent biologic in this area, saw its global net sales rise by 23% to $3.82 billion in its 'Third Quarter 2024 Financial and Operating Results', demonstrating strong commercial interest. This growth in revenue highlights a broader movement towards precision medicine in addressing sinonasal conditions driven by Type 2 inflammation.

Concurrently, progress in minimally invasive sinus surgical procedures is fueling market expansion by providing safer, in-office treatment options. Technologies like balloon sinus dilation and steroid-eluting implants have significantly reduced recovery periods, fostering greater patient acceptance. This increased demand is underpinned by the considerable prevalence of the disease; a November 2024 article in 'Clinical & Experimental Allergy' noted the global pooled prevalence of chronic rhinosinusitis at 8.71%, indicating a large population needing effective care. Consequently, medical device manufacturers are capitalizing on this necessity. Stryker's 'Fourth Quarter and Full Year 2024 Operating Results' from January 2025 showed that its MedSurg and Neurotechnology segment, including the ENT business, achieved net sales of $13.5 billion, an 11.1% increase, driven by consistent procedural demand.

Market Challenge

The considerable financial outlay required for advanced biologic therapies and minimally invasive surgical interventions poses a significant obstacle to the expansion of the Global Chronic Rhinosinusitis Market. Although these treatment options offer substantial clinical advantages for patients with difficult-to-treat conditions, their expensive pricing structures limit broad access. Healthcare systems, particularly those in resource-constrained areas, frequently find it challenging to cover these high costs, resulting in strict reimbursement rules and restricted availability on formularies. As a result, the uptake of these therapies is slowed, compelling patients and providers to opt for more affordable, traditional treatments which may prove less effective for severe cases.

The economic implications of these high-cost interventions are measurable and cause reluctance among payers. The European Rhinologic Society's journal 'Rhinology' reported in 2025 that the average direct cost per patient per year for biological treatments was approximately 60,026 EUR, significantly surpassing that of conventional surgical procedures. Such elevated expenses discourage insurance providers from approving these treatments as initial options. This financial friction directly reduces the potential revenue for manufacturers, thereby curbing the market's overall growth despite a clear clinical need for better therapeutic results.

Market Trends

The emergence of novel sustained-release intranasal delivery systems is overcoming the shortcomings of traditional sprays and implants. These innovative exhalation delivery methods leverage the patient's own breath to propel medication deep into the sinonasal cavities, thereby enhancing drug deposition without the need for invasive interventions. This approach is gaining favor among medical specialists aiming to maximize the effectiveness of topical steroids. The commercial success of specialized innovators provides evidence of this increasing adoption; for example, Optinose announced in January 2025 its 'Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue' press release, reporting net product revenue of $22.4 million for the quarter, which indicates ongoing demand for its advanced delivery platform.

At the same time, the integration of Augmented Reality (AR) into endoscopic sinus surgery is significantly improving both visualization and anatomical accuracy. Surgeons are increasingly employing navigation systems that project three-dimensional anatomical data directly onto the surgical field, thereby minimizing the risk of complications during intricate procedures. This development aligns with the broader industry objective of high-precision interventions designed to reduce tissue trauma. Consequently, there is strong sustained demand for sophisticated capital equipment as hospitals continue to modernize their surgical facilities. Medtronic's 'Full Year and Fourth Quarter Fiscal 2024 Financial Results' in May 2024 highlighted high-single digit growth within its ENT business, part of the Specialty Therapies division, attributed to robust sales of power capital and navigation technologies.

Key Market Players

  • Lyra Therapeutics
  • Novartis AG
  • Medtronic plc
  • GlaxoSmithKline plc
  • AstraZeneca Plc
  • Sanofi AG
  • Dr. Reddy's Laboratories Ltd.
  • Stryker Corporation
  • Bayer AG
  • Smith & Nephew Plc

Report Scope

In this report, the Global Chronic Rhinosinusitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Rhinosinusitis Market, By Disease Phenotype

  • Non-Eosinophilic Chronic Rhinosinusitis
  • Eosinophilic Chronic Rhinosinusitis
  • Infectious Chronic Rhinosinusitis
  • Allergic Fungal Rhinosinusitis
  • Others

Chronic Rhinosinusitis Market, By Treatment Type

  • Medical Devices
  • Drugs
  • Nasal Drops
  • Steroid Nasal Sprays
  • Surgery
  • Others

Chronic Rhinosinusitis Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Chronic Rhinosinusitis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Rhinosinusitis Market.

Available Customizations:

Global Chronic Rhinosinusitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Rhinosinusitis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Phenotype (Non-Eosinophilic Chronic Rhinosinusitis, Eosinophilic Chronic Rhinosinusitis, Infectious Chronic Rhinosinusitis, Allergic Fungal Rhinosinusitis, Others)
    • 5.2.2. By Treatment Type (Medical Devices, Drugs, Nasal Drops, Steroid Nasal Sprays, Surgery, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Chronic Rhinosinusitis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Phenotype
    • 6.2.2. By Treatment Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chronic Rhinosinusitis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Phenotype
        • 6.3.1.2.2. By Treatment Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Chronic Rhinosinusitis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Phenotype
        • 6.3.2.2.2. By Treatment Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Chronic Rhinosinusitis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Phenotype
        • 6.3.3.2.2. By Treatment Type
        • 6.3.3.2.3. By Distribution Channel

7. Europe Chronic Rhinosinusitis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Phenotype
    • 7.2.2. By Treatment Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chronic Rhinosinusitis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Phenotype
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Chronic Rhinosinusitis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Phenotype
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Chronic Rhinosinusitis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Phenotype
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Chronic Rhinosinusitis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Phenotype
        • 7.3.4.2.2. By Treatment Type
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Chronic Rhinosinusitis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Phenotype
        • 7.3.5.2.2. By Treatment Type
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Chronic Rhinosinusitis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Phenotype
    • 8.2.2. By Treatment Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Chronic Rhinosinusitis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Phenotype
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Chronic Rhinosinusitis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Phenotype
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Chronic Rhinosinusitis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Phenotype
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Chronic Rhinosinusitis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Phenotype
        • 8.3.4.2.2. By Treatment Type
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Chronic Rhinosinusitis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Phenotype
        • 8.3.5.2.2. By Treatment Type
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Chronic Rhinosinusitis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Phenotype
    • 9.2.2. By Treatment Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Chronic Rhinosinusitis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Phenotype
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Chronic Rhinosinusitis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Phenotype
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Chronic Rhinosinusitis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Phenotype
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Distribution Channel

10. South America Chronic Rhinosinusitis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Phenotype
    • 10.2.2. By Treatment Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Chronic Rhinosinusitis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Phenotype
        • 10.3.1.2.2. By Treatment Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Chronic Rhinosinusitis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Phenotype
        • 10.3.2.2.2. By Treatment Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Chronic Rhinosinusitis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Phenotype
        • 10.3.3.2.2. By Treatment Type
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Chronic Rhinosinusitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Lyra Therapeutics
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Medtronic plc
  • 15.4. GlaxoSmithKline plc
  • 15.5. AstraZeneca Plc
  • 15.6. Sanofi AG
  • 15.7. Dr. Reddy's Laboratories Ltd.
  • 15.8. Stryker Corporation
  • 15.9. Bayer AG
  • 15.10. Smith & Nephew Plc

16. Strategic Recommendations

17. About Us & Disclaimer